Go to
current issue
-
Bridging the diagnostic gap in Alzheimer's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18
No Abstract
-
Progress and future directions in spinal cord injury trials Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Karlo M Pedro, Michael G Fehlings
No Abstract
-
Autoimmune encephalitis: diagnostic challenges and tensions Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Russell C Dale
No Abstract
-
Ischaemic stroke in 2024: progress on multiple fronts Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Pengfei Yang, Yongxin Zhang, Jianmin Liu
No Abstract
-
Advances in dementia research and clinical care in 2024 Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Tammie Benzinger
No Abstract
-
Highlights in traumatic brain injury research in 2024 Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Virginia Newcombe, Elisa R Zanier
No Abstract
-
Headache research in 2024: new data on migraine prevention Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Patricia Pozo-Rosich
No Abstract
-
Epilepsy research highlights in 2024: avenues for discovery Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Gretchen L Birbeck
No Abstract
-
Movement disorders in 2024: peripheral and outside the box Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Brit Mollenhauer, Chin-Hsien Lin
No Abstract
-
Multiple sclerosis in 2024: evolving evidence and new hopes Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Maria Pia Amato, Emilio Portaccio
No Abstract
-
Advances in neuromuscular disorders 2024 Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Jeffrey D Rothstein, Ahmet Hoke, Payam Mohassel
No Abstract
-
Advances in sleep research in 2024 Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Yves Dauvilliers
No Abstract
-
Infectious diseases research in 2024: insights into dementia Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Robyn S Klein
No Abstract
-
Neuroscience research in 2024: advances in blood biomarkers and brain omics Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Amy K Y Fu, Nancy Y Ip
No Abstract
-
Correction to Lancet Neurol 2024; 23: 1183–84 Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18
Teng H, Liu Z, Xu J. Surgical treatment for chronic subdural haematoma. Lancet Neurol 2024; 23: 1183–84—In this Correspondence, Jianguo Xu should have been marked as the corresponding author, with the corresponding email address xujg@scu.edu.cn. This correction has been made to the online version as of Dec 18, 2024.
-
Correction to Lancet Neurol 2024; 23: 1205–13 Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18
Sheth KN, Albers GW, Saver JL, et al. Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Neurol 2024; 23: 1205–13 —In this Article, the CHARM Trial investigators and the appendix have been updated. This correction has been made as of Dec 18, 2024.
-
Cristina Sampaio: bringing rigour to research in movement disorders Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Udani Samarasekera
No Abstract
-
Patrikios syndrome and SOD1 ALS Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Peter M Andersen, Michael Benatar
No Abstract
-
-
Neurology takes centre stage at the Edinburgh Festival Fringe Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Peter Ranscombe
No Abstract
-
Turning childhood experience of neurological disease into art Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Joe Moody
No Abstract
-
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Norbert Weidner, Rainer Abel, Doris Maier, Klaus Röhl, Frank Röhrich, Michael Baumberger, Margret Hund-Georgiadis, Marion Saur, Jesús Benito, Kerstin Rehahn, Mirko Aach, Andreas Badke, Jiri Kriz, Katalin Barkovits, Tim Killeen, Lynn Farner, Maryam Seif, Michèle Hubli, Katrin Marcus, Michael A Maurer, Armin Curt
BackgroundSpinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute
-
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Gemma Olivé-Cirera, Elianet Fonseca, Li-Wen Chen, Anna Fetta, Eugenia Martínez-Hernández, Mar Guasp, Veronica González-Álvarez, Verónica Delgadillo, Verónica Cantarín-Extremera, María Jiménez-Legido, Lorena Monge-Galindo, Ana Felipe, Beatriz Beseler, Eulàlia Turón-Viñas, Joaquín Fernández-Ramos, Maria J Martínez-González, Maria Vázquez-López, Luisa Arrabal Fernandez, Mireia Alvarez-Molinero, Beatriz
BackgroundThe usefulness of current diagnostic approaches in children with suspected autoimmune encephalitis is unknown. We aimed to assess the diagnosis of autoimmune encephalitis in clinical practice and to compare the performance of two international diagnostic algorithms (one intended for patients of any age [general], the other intended for paediatric patients), with particular emphasis on the
-
Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention Lancet Neurol. (IF 46.5) Pub Date : 2024-12-18 Michael Benatar, Janice Robertson, Peter Munch Andersen
Pathogenic variants in the superoxide dismutase 1 (SOD1) gene were the first identified genetic cause of amyotrophic lateral sclerosis (ALS), in 1993. This discovery enabled the development of transgenic rodent models for studying the biology of SOD1 ALS. The understanding that SOD1 ALS is driven by a toxic gain-of-function mutation has led to therapeutic strategies that aim to lower concentrations
-
Diagnosis and management of status epilepticus: improving the status quo Lancet Neurol. (IF 46.5) Pub Date : 2024-12-02 Jennifer V Gettings, Fatemeh Mohammad Alizadeh Chafjiri, Archana A Patel, Simon Shorvon, Howard P Goodkin, Tobias Loddenkemper
Status epilepticus is a common neurological emergency that is characterised by prolonged or recurrent seizures without recovery between episodes and associated with substantial morbidity and mortality. Prompt recognition and targeted therapy can reduce the risk of complications and death associated with status epilepticus, thereby improving outcomes. The most recent International League Against Epilepsy
-
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial Lancet Neurol. (IF 46.5) Pub Date : 2024-11-29 Shuya Li, Hong-Qiu Gu, Baoyu Feng, Hao Li, Xuechun Wang, Qiang Dong, Dongsheng Fan, Yun Xu, Suiqiang Zhu, Hongguo Dai, Yan Wei, Ziran Wang, Guozhi Lu, Yutong Ma, Zixiao Li, Yilong Wang, Xia Meng, Xingquan Zhao, Liping Liu, Yongjun Wang
BackgroundIntra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke. Given the global shortage of thrombolytics, we aimed to assess the non-inferiority of intravenous recombinant human prourokinase compared with alteplase in patients with acute ischaemic stroke who were ineligible for or who refused endovascular thrombectomy. MethodsPROST-2
-
Reconsidering prourokinase for acute ischaemic stroke Lancet Neurol. (IF 46.5) Pub Date : 2024-11-29 Guillaume Turc, Thanh N Nguyen
No Abstract
-
A cautionary view on blood pressure lowering in patients with acute ischaemic stroke receiving reperfusion therapy Lancet Neurol. (IF 46.5) Pub Date : 2024-11-25 Nyika D Kruyt, Paul J Nederkoorn, Else Charlotte Sandset, Patrick Lyden, Lili Song, Craig S Anderson
No Abstract
-
Creative neurorehabilitation: the art of intervention Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Jules Morgan
No Abstract
-
United action is needed to prioritise brain health Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20
No Abstract
-
Antiplatelet therapy after intracerebral haemorrhage Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Wendy C Ziai, Santosh B Murthy, Christopher P Kellner
No Abstract
-
Ischaemic brain oedema remains a major unmet need Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Alejandro A Rabinstein
No Abstract
-
The amyloid clock: mapping Alzheimer's disease in Down syndrome Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Michael S Rafii
No Abstract
-
A new seed amplification assay to diagnose multiple system atrophy Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 James A Wiseman, Glenda M Halliday, Birger Victor Dieriks
No Abstract
-
REM sleep behaviour disorder and α-synuclein Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Bradley F Boeve, Tanis J Ferman
No Abstract
-
Globalisation of the pharmacological treatment of migraine Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Massimo Leone
No Abstract
-
PACAP pathway: a new frontier in migraine prevention Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Mario Fernando Prieto Peres
No Abstract
-
Surgical treatment for chronic subdural haematoma Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Muhammed Amir Essibayi, Deepak Khatri, David Altschul
No Abstract
-
Surgical treatment for chronic subdural haematoma Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Haibo Teng, Zhiyong Liu, Jianguo Xu
No Abstract
-
Surgical treatment for chronic subdural haematoma Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Liang Wu, Guoyi Gao, Weiming Liu
No Abstract
-
Surgical treatment for chronic subdural haematoma –Authors’ reply Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Mads Hjortdal Grønhøj, Frantz Rom Poulsen
No Abstract
-
Effects of climate change on the brain: an environmental neurology perspective Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Jacques Reis, Alain Buguet, Manny W Radomski, Gustavo C Román, Peter S Spencer
No Abstract
-
Effects of climate change on the brain: an environmental neurology perspective – Authors’ reply Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Sanjay M Sisodiya, Mark A Maslin, Marina Romanello, Michael G Hanna
No Abstract
-
Correction to Lancet Neurol 2024; 23: 961–62 Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20
Monfrini E, Minardi R, Valzania F, Calandra-Buonaura G, Mandich P, Di Fonzo A. RAB32 mutation in Parkinson's disease. Lancet Neurol 2024; 23: 961–62—The appendix has been updated to include a list of ParkNet Study Group members who were involved in this project. This correction has been made as of Nov 20, 2024.
-
Frank Longo: taking on Alzheimer's disease Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Henna Hundal
No Abstract
-
The legacy of Egas Moniz Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Maria Francisca Rocha, Rosa Maria Rodrigues, Arpan R Mehta
No Abstract
-
-
200 years since the death of James Parkinson Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Marcus V Della Coletta, Helio A G Teive, Andrew Lees
No Abstract
-
The elusive foundations of creativity Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Rui Araújo
No Abstract
-
The woman who was not there Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Marco De Ambrogi
No Abstract
-
Monitoring brainwaves while gallery visitors view artworks Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Peter Ranscombe
No Abstract
-
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Qingyuan Liu, Shaohua Mo, Jun Wu, Xianzeng Tong, Kaiwen Wang, Xu Chen, Shanwen Chen, Shuaiwei Guo, Xiong Li, Mingde Li, Lei Peng, Xinguo Sun, Yang Wang, Jianjun Sun, Jun Pu, Kaige Zheng, Jiaming Zhang, Yang Liu, Yi Yang, Zheng Wen, Pengjun Jiang
BackgroundPatients with non-traumatic intracerebral haemorrhage have a substantial risk of major adverse cardiovascular and cerebrovascular events, including ischaemic stroke, after surgery. The optimal timing of antiplatelet therapy after surgery for spontaneous intracerebral haemorrhage in patients at high risk of postoperative ischaemic events has not been characterised. We aimed to investigate
-
Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Kevin N Sheth, Gregory W Albers, Jeffrey L Saver, Bruce C V Campbell, Bradley J Molyneaux, H E Hinson, Charlotte Cordonnier, Thorsten Steiner, Kazunori Toyoda, Max Wintermark, Ross Littauer, Jessica Collins, Nisha Lucas, Raul G Nogueira, J Marc Simard, Michael Wald, Kate Dawson, W Taylor Kimberly
BackgroundNo treatment is available to prevent brain oedema, which can occur after a large hemispheric infarction. Glibenclamide has previously been shown to improve functional outcome and reduce neurological or oedema-related death in patients younger than 70 years who were at risk of brain oedema after an acute ischaemic stroke. We aimed to assess whether intravenous glibenclamide could improve functional
-
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Emily K Schworer, Matthew D Zammit, Jiebiao Wang, Benjamin L Handen, Tobey Betthauser, Charles M Laymon, Dana L Tudorascu, Annie D Cohen, Shahid H Zaman, Beau M Ances, Mark Mapstone, Elizabeth Head, Bradley T Christian, Sigan L Hartley
BackgroundAdults with Down syndrome are at risk for Alzheimer's disease. Natural history cohort studies have characterised the progression of Alzheimer's disease biomarkers in people with Down syndrome, with a focus on amyloid β-PET and tau-PET. In this study, we aimed to leverage these well characterised imaging biomarkers in a large cohort of individuals with Down syndrome, to examine the timeline
-
Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Yihua Ma, Carly M Farris, Sandrina Weber, Sebastian Schade, Hieu Nguyen, Alexandra Pérez-Soriano, Darly M Giraldo, Manel Fernández, Marta Soto, Ana Cámara, Celia Painous, Esteban Muñoz, Francesc Valldeoriola, Maria J Martí, Jordi Clarimon, Pekka Kallunki, Thong Chi Ma, Roy N Alcalay, Bárbara Fernandez Gomes, Kaj Blennow, Luis Concha-Marambio
BackgroundThe pathological hallmarks of multiple system atrophy and Parkinson's disease are, respectively, misfolded-α-synuclein-laden glial cytoplasmic inclusions and Lewy bodies. CSF-soluble misfolded α-synuclein aggregates (seeds) are readily detected in people with Parkinson's disease by α-synuclein seed amplification assay (synSAA), but identification of seeds associated with multiple system atrophy
-
Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Gerard Mayà, Alex Iranzo, Carles Gaig, Raquel Sánchez-Valle, Monica Serradell, Laura Molina-Porcel, Joan Santamaria, Ellen Gelpi, Iban Aldecoa
BackgroundIdiopathic rapid eye movement (REM) sleep behaviour disorder (IRBD) is thought to be an early stage of α-synuclein-related neurodegenerative diseases. Nevertheless, the definitive identification of its biological substrate can be determined only by post-mortem neuropathology. We aimed to describe the post-mortem neuropathology of individuals with IRBD who developed or did not develop a neurodegenerative
-
Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment Lancet Neurol. (IF 46.5) Pub Date : 2024-11-20 Florian Krismer, Alessandra Fanciulli, Wassilios G Meissner, Elizabeth A Coon, Gregor K Wenning
Multiple system atrophy is an adult-onset, sporadic, and progressive neurodegenerative disease. People with this disorder report a wide range of motor and non-motor symptoms. Overlap in the clinical presentation of multiple system atrophy with other movement disorders (eg, Parkinson's disease and progressive supranuclear palsy) is a concern for accurate and timely diagnosis. Over the past 5 years,
-
The global dimension of Parkinson's disease genetics Lancet Neurol. (IF 46.5) Pub Date : 2024-10-21 Thomas Gasser
No Abstract
-
Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic Lancet Neurol. (IF 46.5) Pub Date : 2024-10-21 Prof Shen-Yang Lim MD, Ai Huey Tan MD PhD, Azlina Ahmad-Annuar PhD, Prof Njideka Ulunma Okubadejo MD, Prof Katja Lohmann PhD, Prof Huw R Morris PhD FRCP, Tzi Shin Toh BSc, Yi Wen Tay BSc, Lara M Lange MD, Sara Bandres-Ciga PhD, Ignacio Mata PhD, Jia Nee Foo PhD, Esther Sammler PhD, Joshua Chin Ern Ooi MBBCh, Alastair J Noyce MD PhD, Natascha Bahr, Wei Luo MD PhD, Rajeev Ojha MD, Andrew B Singleton
Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, caused by a mutation in α-synuclein, and with the subsequent identification of multiple other causative genes and associated loci. Genetic studies provide insights into the phenotypic heterogeneity and global distribution of Parkinson's disease. By shedding light on the underlying
-
Changing the landscape of neurological education Lancet Neurol. (IF 46.5) Pub Date : 2024-10-16 Lukas Sveikata, Indrit Bègue, Raphael Guzman, Luca Remonda, Claudio LA Bassetti
No Abstract
更新日期：2024-12-19
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号